What is Beauty Health Co?
The Beauty Health Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells esthetic technologies and products in the Americas, the Asia-Pacific, Europe, the Middle East, and Africa.
SKIN · Verdict
Moderate reward · elevated risk
SKIN has limited near-term tailwinds — balance sheet and cash flow weigh on the model output.
Based on 88% data coverage
SKIN · Verdict
Net debt/EBITDA 19.2×
3% free-cash-flow margin
-9% net margin · -19% ROE
Rev +8.7% CAGR · earnings -57.5%
Model-based scoring. For information only — not financial advice.
The Beauty Health Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells esthetic technologies and products in the Americas, the Asia-Pacific, Europe, the Middle East, and Africa. The company's flagship product is HydraFacial, which enhances the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. The company is listed on the NASDAQ in USA, operating in the Consumer Defensive sector, with a market capitalisation of 132.60M.
The scoring profile indicates limited reward potential at this time, with valuation and momentum offering the most support. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.
For informational purposes only. Not financial advice.